CEO of Entrada Therapeutics
CEO of Entrada Therapeutics
Quick Links
E
Nathan J. Dowden
CEO of Entrada Therapeutics
Education
B.S. in Finance from University of Connecticut, MBA from University of Chicago Booth School of Business
Sector of Economy
Healthcare
Born
January 1, 1983 - 42 years ago
CEO of Entrada Therapeutics for
1 year 5 months (Jan 2024 - Present)
Previous Experience
Chief Operating Officer at Entrada Therapeutics, Senior VP at Rubius Therapeutics
Rivals
Competitors/colleagues of Nathan J. Dowden
Holdings
See how much did Nathan J. Dowden make over time.
Holdings and trades for CEO of Entrada Therapeutics
Holdings and trades for CEO of Entrada Therapeutics
Mar 18, 2025
Total Stock Sold
$1.47M
TRDA
$1.47M
89,080 TRDA shares
What if they kept their stock?
If Nathan J. Dowden didn't sell their stock, today they would have:
Extra TRDA89,080 shares worth $2.13M.
This is 44.95% and $661.63K more than what they got when they sold the stock.
Insider Trading
See recent insider trades of Nathan J. Dowden.
TRDA
$13.55K
TRDA at $16.00/share
Sep 26, 2024
Sale
TRDA
$34.85K
TRDA at $15.13/share
Sep 6, 2024
Sale
TRDA
$446.52K
TRDA at $16.48/share
Aug 16, 2024
Sale
TRDA
$22.50K
TRDA at $12.32/share
Mar 6, 2024
Sale
TRDA
93,100 shares
TRDA
Mar 1, 2024
Received
TRDA
$13.33K
TRDA at $13.72/share
Sep 1, 2023
Sale
TRDA
14,200 shares
TRDA
Sep 1, 2023
Received
TRDA
$127.92K
TRDA at $18.02/share
Jul 10, 2023
Sale
TRDA
$247.37K
TRDA at $15.48/share
Jun 20, 2023
Sale
TRDA
14,200 shares
TRDA
Mar 1, 2023
Received
Compensation History
See how much did Nathan J. Dowden make over time.
No compensation data available for Nathan J. Dowden yet. Come back soon!
Other Entrada Therapeutics CEOs
Here are other CEOs of Entrada Therapeutics